Cryo Cell International Inc: Form 10-Q for the period ended Feb 28, 2023
Filed with the SEC on Apr 21, 2023 and accepted by EDGAR at Apr 21, 2023, 20:32 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-02-28. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-12-01 to 2023-02-28 | $7.8m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2022-12-01 to 2023-02-28 | $2.1m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2022-12-01 to 2023-02-28 | $78.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2022-12-01 to 2023-02-28 | $3.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-12-01 to 2023-02-28 | $1.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-12-01 to 2023-02-28 | $466.2k | us-gaap:InterestExpense |
| Income tax | 3 months2022-12-01 to 2023-02-28 | $447.7k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-12-01 to 2023-02-28 | $766.8k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-12-01 to 2023-02-28 | $0.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-12-01 to 2023-02-28 | $0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-12-01 to 2023-02-28 | 8,474,737 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-12-01 to 2023-02-28 | $1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-12-01 to 2023-02-28 | $375.6k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 3 months2022-12-01 to 2023-02-28 | $243.2k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-02-28 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-02-28 | $10.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-02-28 | $66.1m | us-gaap:Assets |
| Current liabilities | At period end2023-02-28 | $18.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-02-28 | $66.8m | us-gaap:Liabilities |
| Long-term debt | At period end2023-02-28 | $8.7m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2023-02-28 | −$687.5k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-013868. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.